The Medical Letter on Drugs and Therapeutics
PSA Reconsidered
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Three recent publications have focused attention once more on the contentious question of whether men should be screened for prostate cancer by measuring serum concentrations of prostate specific antigen (PSA).

USPSTF RECOMMENDATION — The United States Preventive Services Task Force (USPSTF) has updated its 2008 recommendation in which it advised against PSA screening in men ≥75 years old. Now it recommends against PSA-based screening in men of any age because, in effect, the benefits have not been shown to outweigh the harms of subsequent diagnostic procedures and treatments.1

SOME EXPERTS DISAGREE — In the same issue of the same journal, an ad hoc group of urologists, oncologists, other specialists and primary care physicians expressed its disagreement with the USPSTF recommendation. This group pointed out that since widespread PSA testing began in the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: PSA Reconsidered
Article code: 1396a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian